1.Dietary Status of Preterm Infants and the Need for Community Care
Ji Su JEON ; Won Hee SEO ; Eun mi WHANG ; Bu Kyung KIM ; Eui Kyung CHOI ; Jang Hoon LEE ; Jeong Hee SHIN ; Young Shin HAN ; Sang-Jin CHUNG
Korean Journal of Community Nutrition 2022;27(4):273-285
		                        		
		                        			 Objectives:
		                        			This study compared the nutritional intakes of early and late preterm infants in a neonatal intensive care unit (NICU) and at home. The dietary problems and the need for community care services for premature infants were further investigated. 
		                        		
		                        			Methods:
		                        			This is a cross-sectional and descriptive study on 125 preterm infants and their parents (Early preterm n = 70, Late preterm n = 55). The data were collected by surveying the parents of preterm infants and from hospital medical records. 
		                        		
		                        			Results:
		                        			No significant differences were obtained between the early and late preterm infant groups when considering the proportion of feeding types in the NICU and at home. Early preterm infants were fed with a greater amount of additional calories at home and had more hours of tube feeding (P = 0.022). Most preterm infants had feeding problems. However, there was no significant difference between early and late preterm infants in the mental pain of parents, sleeping, feeding, and weaning problems at home. Many parents of preterm babies had no external support, and more than half the parents required community care to take care of their preterm babies. 
		                        		
		                        			Conclusions
		                        			Regardless of the gestational age, most preterm infants have several problems with dietary intake. Our study indicates the need to establish community care services for preterm infants. 
		                        		
		                        		
		                        		
		                        	
2.Repeat Descemet Membrane Endothelial Keratoplasty after Descemet Membrane Endothelial Keratoplasty Graft Failure
Gee-Hyun KIM ; Min Ji HA ; Dong Jin CHANG ; Woong Joo WHANG ; Yong-Soo BYUN ; Hyung Bin HWANG ; Kyung Sun NA ; Chang Rae RHO ; Hyun Soo LEE ; So Hyang CHUNG ; Eun Chul KIM ; Yang Kyung CHO ; Hyun Seung KIM ; Man Soo KIM ; Ho Sik HWANG
Journal of the Korean Ophthalmological Society 2021;62(5):702-708
		                        		
		                        			Purpose:
		                        			To report a case of secondary Descemet membrane endothelial keratoplasty (DMEK) for graft failure after primary DMEK.Case summary: A 47-year-old female underwent primary DMEK in her left eye with a diagnosis of Fuchs’ endothelial dystrophy. At 6 weeks later, corneal stromal edema with epithelial and subepithelial bullae was first observed. From that point on, the condition of the cornea and the visual acuity continued to degrade. After 7 months, a second DMEK procedure (i.e., a repeat DMEK) for graft failure was performed successfully without any complications. Since the second procedure, the cornea has been clear, and the best-corrected visual acuity has remained at 0.6 for 8 months. 
		                        		
		                        			Conclusions
		                        			To manage graft failure after primary DMEK, we performed a second DMEK procedure. The removal of the previous graft was easy, and there were no complications. Thus, repeat DMEK may be a feasible procedure.
		                        		
		                        		
		                        		
		                        	
3.Repeat Descemet Membrane Endothelial Keratoplasty after Descemet Membrane Endothelial Keratoplasty Graft Failure
Gee-Hyun KIM ; Min Ji HA ; Dong Jin CHANG ; Woong Joo WHANG ; Yong-Soo BYUN ; Hyung Bin HWANG ; Kyung Sun NA ; Chang Rae RHO ; Hyun Soo LEE ; So Hyang CHUNG ; Eun Chul KIM ; Yang Kyung CHO ; Hyun Seung KIM ; Man Soo KIM ; Ho Sik HWANG
Journal of the Korean Ophthalmological Society 2021;62(5):702-708
		                        		
		                        			Purpose:
		                        			To report a case of secondary Descemet membrane endothelial keratoplasty (DMEK) for graft failure after primary DMEK.Case summary: A 47-year-old female underwent primary DMEK in her left eye with a diagnosis of Fuchs’ endothelial dystrophy. At 6 weeks later, corneal stromal edema with epithelial and subepithelial bullae was first observed. From that point on, the condition of the cornea and the visual acuity continued to degrade. After 7 months, a second DMEK procedure (i.e., a repeat DMEK) for graft failure was performed successfully without any complications. Since the second procedure, the cornea has been clear, and the best-corrected visual acuity has remained at 0.6 for 8 months. 
		                        		
		                        			Conclusions
		                        			To manage graft failure after primary DMEK, we performed a second DMEK procedure. The removal of the previous graft was easy, and there were no complications. Thus, repeat DMEK may be a feasible procedure.
		                        		
		                        		
		                        		
		                        	
4.Normal Postoperative Computed Tomography Findings after a Variety of Pancreatic Surgeries.
Ji Won SEO ; Ho Kyoung HWANG ; Minwook LEE ; Ki Whang KIM ; Chang Moo KANG ; Myeong Jin KIM ; Yong Eun CHUNG
Korean Journal of Radiology 2017;18(2):299-308
		                        		
		                        			
		                        			Pancreatic surgery remains the only curative treatment for pancreatic neoplasms, and plays an important role in the management of medically intractable diseases. Since the original Whipple operation in the 20th century, surgical techniques have advanced, resulting in decreased postoperative complications and better clinical outcomes. Normal postoperative imaging findings vary greatly depending on the surgical technique used. Radiologists are required to be familiar with the normal postoperative imaging findings, in order to distinguish from postoperative complications or tumor recurrence. In this study, we briefly review a variety of surgical techniques for the pancreas, and present the normal postoperative computed tomography findings.
		                        		
		                        		
		                        		
		                        			Pancreas
		                        			;
		                        		
		                        			Pancreatic Neoplasms
		                        			;
		                        		
		                        			Postoperative Complications
		                        			;
		                        		
		                        			Recurrence
		                        			
		                        		
		                        	
5.Poloxamer 407 Hydrogels for Intravesical Instillation to Mouse Bladder: Gel-Forming Capacity and Retention Performance.
Sang Hyun KIM ; Sung Rae KIM ; Ho Yub YOON ; In Ho CHANG ; Young Mi WHANG ; Min Ji CHO ; Myeong Joo KIM ; Soo Yeon KIM ; Sang Jin LEE ; Young Wook CHOI
Korean Journal of Urological Oncology 2017;15(3):178-186
		                        		
		                        			
		                        			PURPOSE: Poloxamer 407 (P407) thermo-sensitive hydrogel formulations were developed to enhance the retention time in the urinary bladder after intravesical instillation. MATERIALS AND METHODS: P407 hydrogels (P407Gels) containing 0.2 w/w% fluorescein isothiocyanate dextran (FD, MW 4 kDa) as a fluorescent probe were prepared by the cold method with different concentrations of the polymer (20, 25, and 30 w/w%). The gel-forming capacities were characterized in terms of gelation temperature (G-Temp), gelation time (G-Time), and gel duration (G-Dur). Homogenous dispersion of the probe throughout the hydrogel was observed by using fluorescence microscopy. The in vitro bladder simulation model was established to evaluate the retention and drug release properties. P407Gels in the solution state were administered to nude mice via urinary instillation, and the in vivo retention behavior of P407Gels was visualized by using an in vivo imaging system (IVIS). RESULTS: P407Gels showed a thermo-reversible phase transition at 4℃ (refrigerated; sol) and 37℃ (body temperature; gel). The G-Temp, G-Time, and G-Dur of FD-free P407Gels were approximately 10℃–20℃, 12–30 seconds, and 12–35 hours, respectively, and were not altered by the addition of FD. Fluorescence imaging showed that FD was spread homogenously in the gelled P407 solution. In a bladder simulation model, even after repeated periodic filling-emptying cycles, the hydrogel formulation displayed excellent retention with continuous release of the probe over 8 hours. The FD release from P407Gels and the erosion of the gel, both of which followed zero-order kinetics, had a linear relationship (r²=0.988). IVIS demonstrated that the intravesical retention time of P407Gels was over 4 hours, which was longer than that of the FD solution ( < 1 hour), even though periodic urination occurred in the mice. CONCLUSIONS: FD release from P407Gels was erosion-controlled. P407Gels represent a promising system to enhance intravesical retention with extended drug delivery.
		                        		
		                        		
		                        		
		                        			Administration, Intravesical*
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Dextrans
		                        			;
		                        		
		                        			Drug Liberation
		                        			;
		                        		
		                        			Fluorescein
		                        			;
		                        		
		                        			Hydrogel*
		                        			;
		                        		
		                        			Hydrogels*
		                        			;
		                        		
		                        			In Vitro Techniques
		                        			;
		                        		
		                        			Kinetics
		                        			;
		                        		
		                        			Methods
		                        			;
		                        		
		                        			Mice*
		                        			;
		                        		
		                        			Mice, Nude
		                        			;
		                        		
		                        			Microscopy, Fluorescence
		                        			;
		                        		
		                        			Optical Imaging
		                        			;
		                        		
		                        			Phase Transition
		                        			;
		                        		
		                        			Poloxamer*
		                        			;
		                        		
		                        			Polymers
		                        			;
		                        		
		                        			Urinary Bladder*
		                        			;
		                        		
		                        			Urination
		                        			
		                        		
		                        	
6.Identification of Downstream Genes of the mTOR Pathway that Predict Recurrence and Progression in Non-Muscle Invasive High-Grade Urothelial Carcinoma of the Bladder.
Subin JIN ; In Ho CHANG ; Jin Wook KIM ; Young Mi WHANG ; Ha Jeong KIM ; Soon Auck HONG ; Tae Jin LEE
Journal of Korean Medical Science 2017;32(8):1327-1336
		                        		
		                        			
		                        			Microarray analysis was used to investigate the lack of identified mammalian target of rapamycin (mTOR) pathway downstream genes to overcome cross-talk at non-muscle invasive high-grade (HG)-urothelial carcinoma (UC) of the bladder, gene expression patterns, gene ontology, and gene clustering by triple (p70S6K, S6K, and eIF4E) small interfering RNAs (siRNAs) or rapamycin in 5637 and T24 cell lines. We selected mTOR pathway downstream genes that were suppressed by siRNAs more than 2-fold, or were up-regulated or down-regulated by rapamycin more than 2-fold. We validated mTOR downstream genes with immunohistochemistry using a tissue microarray (TMA) of 125 non-muscle invasive HG-UC patients and knockout study to evaluate the synergistic effect with rapamycin. The microarray analysis selected mTOR pathway downstream genes consisting of 4 rapamycin up-regulated genes (FABP4, H19, ANXA10, and UPK3A) and 4 rapamycin down-regulated genes (FOXD3, ATP7A, plexin D1, and ADAMTS5). In the TMA, FABP4, and ATP7A were more expressed at T1 and FOXD3 was at Ta. ANXA10 and ADAMTS5 were more expressed in tumors ≤ 3 cm in diameter. In a multivariate Cox regression model, ANXA10 was a significant predictor of recurrence and ATP7A was a significant predictor of progression in non-muscle invasive HG-UC of the bladder. In an ATP7A knock-out model, rapamycin treatment synergistically inhibited cell viability, wound healing, and invasion ability compared to rapamycin only. Activity of the ANXA10 and ATP7A mTOR pathway downstream genes might predict recurrence and progression in non-muscle invasive HG-UC of the bladder. ATP7A knockout overcomes rapamycin cross-talk.
		                        		
		                        		
		                        		
		                        			Cell Line
		                        			;
		                        		
		                        			Cell Survival
		                        			;
		                        		
		                        			Gene Expression
		                        			;
		                        		
		                        			Gene Ontology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunohistochemistry
		                        			;
		                        		
		                        			Microarray Analysis
		                        			;
		                        		
		                        			Recurrence*
		                        			;
		                        		
		                        			RNA, Small Interfering
		                        			;
		                        		
		                        			Sirolimus
		                        			;
		                        		
		                        			Urinary Bladder Neoplasms
		                        			;
		                        		
		                        			Urinary Bladder*
		                        			;
		                        		
		                        			Wound Healing
		                        			
		                        		
		                        	
7.Manipulating the Angiogenesis by Inflammation.
Myeong Joo KIM ; Subin JIN ; Young Mi WHANG ; In Ho CHANG
Korean Journal of Urological Oncology 2017;15(1):1-10
		                        		
		                        			
		                        			There exists a need to develop strategies that promote neovascularization in virtually all tissue engineering and regenerative medicine efforts. While research typically focuses on understanding and exploiting the role of angiogenic factors and vascular cells on new blood vessel formation, the activity of the immune system is being recognized to impact vascular formation and adaptation. This review will provide both an overview of the relationship of angiogenesis and the immune system, and how biomaterials may be designed to promote favorable angiogenesis by interaction between these 2 systems to promote effective vascularization.
		                        		
		                        		
		                        		
		                        			Angiogenesis Inducing Agents
		                        			;
		                        		
		                        			Biocompatible Materials
		                        			;
		                        		
		                        			Blood Vessels
		                        			;
		                        		
		                        			Immune System
		                        			;
		                        		
		                        			Inflammation*
		                        			;
		                        		
		                        			Regenerative Medicine
		                        			;
		                        		
		                        			Tissue Engineering
		                        			
		                        		
		                        	
8.Genetically Modified Bacteria as Targeted Agent for Cancer.
Subin JIN ; Young Mi WHANG ; In Ho CHANG
Korean Journal of Urological Oncology 2016;14(2):54-62
		                        		
		                        			
		                        			With the emergence of microbiome as a major player in many human diseases, bacteria as therapeutics are gaining significant interest. Whole bacteria or cytotoxic or immunogenic peptides carried by them exert potent anti-tumor effects in the experimental models of cancer. The use of attenuated microorganism (s) e.g., BCG to treat human urinary bladder cancer was found to be superior compared to standard chemotherapy. While bacteria alone may not offer full therapeutic benefits, modifying them with anti-tumor agents, anti-oncogenes or immunogenic antigens, either alone or in combination, will prove to be beneficial. Vectors for delivering shRNAs that target oncogenic products, express tumor suppressor genes and immunogenic proteins have been developed. These approaches have showed promising anti-tumor activity in mouse models against various tumors. These can be potential therapeutics for humans in the future and such therapeutics may become a future alternative or adjunct regimen along with conventional chemotherapy and radiotherapy. In this review, some conceptual and practical issues on how to improve these agents for human applications are discussed.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Bacteria*
		                        			;
		                        		
		                        			Drug Therapy
		                        			;
		                        		
		                        			Genes, Tumor Suppressor
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Microbiota
		                        			;
		                        		
		                        			Models, Theoretical
		                        			;
		                        		
		                        			Mycobacterium bovis
		                        			;
		                        		
		                        			Peptides
		                        			;
		                        		
		                        			Radiotherapy
		                        			;
		                        		
		                        			RNA, Small Interfering
		                        			;
		                        		
		                        			Urinary Bladder Neoplasms
		                        			
		                        		
		                        	
9.Recombinant Bacille Calmette–Guérin for Immunotherapy in Nonmuscle Invasive Bladder Cancer.
Subin JIN ; Young Mi WHANG ; In Ho CHANG
Korean Journal of Urological Oncology 2016;14(3):109-117
		                        		
		                        			
		                        			Intravesical instillation of Mycobacterium bovis bacille Calmette–Guérin (BCG) has been used for treating nonmuscle invasive bladder cancer as the forefront of immunotherapy, but BCG is ineffective in approximately 30–40% of cases and disease recurs in up to 50% of patients. Recently BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, and the genetic control of these mycobacteria is advanced in the search for less toxic and more potent therapeutic agents for bladder cancer immunotherapy. We will discuss current advances in recombinant BCG construction, research, and future directions.
		                        		
		                        		
		                        		
		                        			Administration, Intravesical
		                        			;
		                        		
		                        			BCG Vaccine
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunotherapy*
		                        			;
		                        		
		                        			Mycobacterium bovis
		                        			;
		                        		
		                        			Urinary Bladder Neoplasms*
		                        			;
		                        		
		                        			Urinary Bladder*
		                        			
		                        		
		                        	
10.Quantitative Analysis of the Effect of Iterative Reconstruction Using a Phantom: Determining the Appropriate Blending Percentage.
Hyun Gi KIM ; Yong Eun CHUNG ; Young Han LEE ; Jin Young CHOI ; Mi Suk PARK ; Myeong Jin KIM ; Ki Whang KIM
Yonsei Medical Journal 2015;56(1):253-261
		                        		
		                        			
		                        			PURPOSE: To investigate the optimal blending percentage of adaptive statistical iterative reconstruction (ASIR) in a reduced radiation dose while preserving a degree of image quality and texture that is similar to that of standard-dose computed tomography (CT). MATERIALS AND METHODS: The CT performance phantom was scanned with standard and dose reduction protocols including reduced mAs or kVp. Image quality parameters including noise, spatial, and low-contrast resolution, as well as image texture, were quantitatively evaluated after applying various blending percentages of ASIR. The optimal blending percentage of ASIR that preserved image quality and texture compared to standard dose CT was investigated in each radiation dose reduction protocol. RESULTS: As the percentage of ASIR increased, noise and spatial-resolution decreased, whereas low-contrast resolution increased. In the texture analysis, an increasing percentage of ASIR resulted in an increase of angular second moment, inverse difference moment, and correlation and in a decrease of contrast and entropy. The 20% and 40% dose reduction protocols with 20% and 40% ASIR blending, respectively, resulted in an optimal quality of images with preservation of the image texture. CONCLUSION: Blending the 40% ASIR to the 40% reduced tube-current product can maximize radiation dose reduction and preserve adequate image quality and texture.
		                        		
		                        		
		                        		
		                        			*Algorithms
		                        			;
		                        		
		                        			Artifacts
		                        			;
		                        		
		                        			Contrast Media/diagnostic use
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			*Phantoms, Imaging
		                        			;
		                        		
		                        			Radiation Dosage
		                        			;
		                        		
		                        			Radiographic Image Interpretation, Computer-Assisted/*methods
		                        			;
		                        		
		                        			Signal-To-Noise Ratio
		                        			;
		                        		
		                        			Tomography, X-Ray Computed
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail